PTPN22 and chronic myelogenous leukemia, BCR-ABL1 positive: Over-expression of LYP in a CML cell line, KCL22, demonstrated its interaction with BCR-ABL1 and its downstream target proteins, such as GRB2 protein, thus mitigating BCR-ABL1 leukemogenesis.